Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

Human Pathology

Volumn 23, Issue 9, 1992, Pages 974-979

  Allred, D Craig ^a,b,c,d   Clark, Gary M ^a,b,c,d   Molina, Rafael ^a,b,c,d   Tandon, Atul K ^a,b,c,d   Schnitt, Stuart J ^a,b,c,d   Gilchrist, Kennedy W ^a,b,c,d   Osborne, C Kent ^a,b,c,d   Tormey, Douglass C ^a,b,c,d   McGuire, William L ^a,b,c,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

breast cancer; c erbB 2; HER 2 neu; immunohistochemistry; oncogene

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST DYSPLASIA; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMAN; HYPERPLASIA; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0026793986     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/0046-8177(92)90257-4     Document Type: Article

References (50)

1. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
2. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
3. The c-neu oncogene: An erbB-related gene encoding a 185,000 MW tumour antigen
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. A v-erb related proto-oncogene, c-erbB-2, is distinct from c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma
6. Amplification of a novel v-erbB-related gene in human mammary carcinoma
7. The c-neu gene: An erbB-homologous gene distinct from and unlinked to genes encoding the EFG receptor
8. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
9. Direct interaction of a ligand for the erbB-2 oncogene produced with the EGF receptor and p185 erbB-2
10. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
11. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene
12. Amplification of c-erbB-2 and aggressive human breast tumors
13. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
14. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer
15. Proto-oncogene amplification and human breast tumor phenotype
16. Genetic alterations of c-myc, c-erbB-2, and c-Haras protooncogenes and clinical associations in human breast carcinomas
17. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB2/ear-1
18. Proto-oncogene abonormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease
19. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma
20. HER-2/neu amplification predicts poor survival in node-positive breast cancer
21. HER-2/neu oncogene protein and prognosis in breast cancer
22. neu-Protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
23. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
24. c-erbB-2 expression in benign and malignant breast disease
25. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer
26. Pathological findings from the national surgical adjuvant breast project (protocol B-06): Prognostic significance of erbB-2 protein overexpression in primary breast cancer
27. c-erbB-2 oncoprotein expression in primary human tumors
28. c-erbB-2 expression in correlation to other biological parameters of breast cancer
29. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer
30. Histologic grading of breast cancer
31. Her-2/neu oncoprotein in breast cancer. A comparison of immunohistochemical and Western blot techniques
32. HER-2/neu in node-negative breast cancer. Prognostic significance of overexpression influenced by presence of in situ carcinoma
33. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
34. The evolution of colorectal carcinoma
35. Dysplasia and the natural history of cervical cancer
36. Atypical hyperplastic lesions of the female breast. A long-term follow-up study
37. Anatomic markers of human premalignancy and risk of breast cancer
38. Benign breast disease and risk of subsequent breast cancer: The experience in the nurse's health study
39. Further delineation of patterns of atypical ductal hyperplasia: An analysis of ADH patterns associated with intraductal and invasive breast carcinoma
40. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues
41. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast
42. Cellular and molecular aspects of neoplastic progression in the mammary gland
43. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
44. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
45. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma
46. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
47. ERBB2 amplification in breast cancer with high rate of proliferation
48. In situ distribution of oncogene products and growth factor receptors in breast carcinoma c-erbB-2 oncoprotein EGFR and PDGFR-b-subunit